Compare GORO & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GORO | SWKH |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Precious Metals | Diversified Financial Services |
| Sector | Basic Materials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.0M | 198.4M |
| IPO Year | 2010 | N/A |
| Metric | GORO | SWKH |
|---|---|---|
| Price | $1.24 | $16.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.63 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.8M | 104.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.80 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $99,759,000.00 | N/A |
| Revenue This Year | $25.99 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | $44.33 | ★ $9.18 |
| Revenue Growth | ★ 51.78 | N/A |
| 52 Week Low | $0.43 | $13.32 |
| 52 Week High | $1.87 | $17.90 |
| Indicator | GORO | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 32.19 |
| Support Level | $0.95 | $14.69 |
| Resistance Level | $1.49 | $17.08 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 5.56 | 12.06 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.